Arcus Biosciences (NYSE:RCUS – Get Rating)‘s stock had its “buy” rating reissued by equities researchers at Mizuho in a research report issued on Friday, Benzinga reports. They currently have a $51.00 target price on the stock. Mizuho’s price target would indicate a potential upside of 210.03% from the company’s current price.
Several other equities research analysts also recently weighed in on the stock. Barclays decreased their price target on shares of Arcus Biosciences from $60.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, December 21st. Citigroup decreased their price target on shares of Arcus Biosciences from $42.00 to $40.00 in a research note on Thursday, March 9th. TheStreet downgraded shares of Arcus Biosciences from a “c-” rating to a “d” rating in a research note on Tuesday, February 28th. Finally, Bank of America started coverage on shares of Arcus Biosciences in a research note on Friday, November 18th. They issued a “neutral” rating and a $33.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.
Arcus Biosciences Stock Down 3.0 %
Shares of NYSE RCUS opened at $16.45 on Friday. Arcus Biosciences has a twelve month low of $15.70 and a twelve month high of $39.75. The firm has a fifty day simple moving average of $19.52 and a 200 day simple moving average of $24.06. The company has a market capitalization of $1.20 billion, a PE ratio of -4.42 and a beta of 0.89.
Institutional Inflows and Outflows
About Arcus Biosciences
Arcus Biosciences, Inc engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
- Get a free copy of the StockNews.com research report on Arcus Biosciences (RCUS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.